#07006: Prediction of Efficacy of Hormonal Therapy in Cancer
………………………………………………………………………………………………………………
TECH FIELD(S)
Medical-Diagnostic
………………………………………………………………………………………………………………
FEATURES
Breast cancer is a heterogeneous disease that kills approximately 40,000 women per year. Breast cancer can be subdivided into 5 distinct molecular subtypes that is important clinically because it determines which treatment options are appropriate for each patient and provides information of prognostic value. Luminal A-subtype is one type of breast cancer that is defined as being positive for the estrogen and progesterone receptors (ER+/PR+). It has now been discovered that the FOXA1 protein is correlated with cancer-specific survival (CSS) and is a better predictor of CSS in the luminal A-subtype than the PR receptor that is currently used as positive prognostic indicator in breast cancer.
………………………………………………………………………………………………………………
BENEFITS
- FOXA1 expression is a positive predictor of CSS, thus having value as a prognostic indicator.
- FOXA1 may be useful for determining which patients should receive anti-estrogen therapy thereby potentially limiting the number of patients that needlessly suffer from the inconvenient and unpleasant side effects of these drugs.
………………………………………………………………………………………………………………
INVENTOR(S)
Sunil S. Badve, M.D. and Harikrishna Nakshatri, Ph.D.
………………………………………………………………………………………………………………
INTELLECTUAL PROPERTY STATUS
This technology is the subject matter of provisional patent No. 60/887,290
………………………………………………………………………………………………………………
CONTACT INFORMATION
Jeremy L. Schieler, Ph.D.
351 W. Tenth Street
Indianapolis, IN 46202
(317) 278-1948
………………………………………………………………………………………………………………
Still have a question? Ask here!